{'fraction_non_alphanumeric': 0.044524669073405534, 'fraction_numerical': 0.03309265944645006, 'mean_word_length': 5.275471698113208, 'pattern_counts': {'":': 0, '<': 2, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
EVALUATION OF ANGIOGENIC FACTORS PRODUCED BY HUMAN CHORIOCARCINOMAS

normal gynecologic tissues by using both electrophoretic TRAP assay and Telomerase PCR ELISA kit. 2. To determine a cut-off level to discriminate malignant tissues by PCR ELISA. 3. To compare the efficacy of qualitative (TRAP) and quantitative (ELISA) methods to discriminate malignancy. Materials and Methods: One hundred six cases (48 gynecologic tumors, 29 benign disorders and 29 normal tissues) were subjected to this prospective study. Patients were divided into three according to tissue origin as: Group I (Vulva and cervix), group II (endometrium) and group III (ovary). Telomerase activity among each group was compared between malignant, benign and normal tissues. Results: The percentage of patients with a positive TRAP assay was significantly higher in the malignant group (79,2%) than in the benign group (34,5%). Mean telomerase activity of the malignant tissues detected by PCR ELISA (1,03þ 0,53 units) was significantly higher than normal (0,13þ 0,07 units) and benign tissues (0,37þ 0,25 units) (p< 0,001). The cut-off point was set at 0,42 where the sensitivity was 87,5% and the specificity was 86,2%. There was a significant difference in telomerase activity between malignant, benign and normal tissues within group I, II and III (p< 0,001). Area under the ROC curve was 0,94 for PCR ELISA and 0,81 for TRAP assay and the difference was insignificant. Conclusion: Telomerase activity can be measured in normal, benign and malignant gynecologic tissues. Quantitative and qualitative telomerase assays are equally effective in discriminating malignant gynecologic tissues.